ArticleCancer immunology, immunotherapy : CII2025

Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer.

Ning Mao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.